Deutetrabenazine
Overview
Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults. Its chemical structure is a deuterated form of tetrabenazine, which helps improve pharmacokinetics by altering metabolic pathways.
API suppliers (6)
Suppliers of Deutetrabenazine evidenced by a US FDA Type II Drug Master File or an EU Certificate of Suitability (CEP). Sources: FDA DMF list, EDQM certification database.
Country recorded for 5 of 6 suppliers.
4 of 6 hold a GMP certificate on record in the EU or UK registers
- MAITHRI DRUGS PRIVATE LTDIndia1 active DMF GMP on record
- Hetero Drugs LimitedIndia1 active DMF GMP on record
- APITORIA PHARMA PRIVATE LTDIndia1 active DMF GMP on record
- LUPIN MANUFACTURING SOLUTIONS LTD1 active DMF
- FARMHISPANIA SASpain1 active DMF
- MSN LIFE SCIENCES PRIVATE LIMITEDIndia1 active DMF GMP on record
Patent & exclusivity (US)
Per the FDA Orange Book (11 approved US products), the latest listed US patent on Deutetrabenazine expires 10 Jun 2041. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
Do you supply Deutetrabenazine? Get in front of buyers actively sourcing it.
We route real sourcing requests from pharma buyers to vetted, verified partners — qualified leads, not just a listing. Tell us what you make and we'll be in touch about becoming a Verified Supplier Partner.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 7 days.